Burden of illness among Medicare and Non-Medicare US populations with acquired thrombotic thrombocytopenic purpura

CONCLUSION: This is the first real-world study evaluating burden of illness among aTTP patients in the US across payer types. Despite being treated with TPE, patients with aTTP have lower survival rates in comparison to a matched cohort without aTTP. These findings highlight the need for more effective and novel therapies to reduce disease burden for this population.Key PointsIn US Medicare and managed care populations with aTTP between 2010-2018, aTTP can lead to significant utilization of ICU services due to clinical complications, and/or relapse following hospital dischargeDespite treatment with therapeutic plasma exchange, acute mortality remains high (15.7%) indicating the need for more effective and novel treatments.PMID:33904347 | DOI:10.1080/13696998.2021.1922262
Source: Journal of Medical Economics - Category: Health Management Authors: Source Type: research